Comparative Metabolomics in Diabetes Patients From Sri Lanka and Switzerland (NCT05787457) | Clinical Trial Compass
TerminatedNot Applicable
Comparative Metabolomics in Diabetes Patients From Sri Lanka and Switzerland
Stopped: Insufficient recruitment
Switzerland34 participantsStarted 2014-07-31
Plain-language summary
This study is a case-control study, where the assumed different subtypes of type 2 diabetes in people of Tamil ethnicity and Swiss origin living in Bern, Switzerland will be examined by measuring the metabolite profiles and the corresponding genetic background as well as ethnic differences in fat distribution performed by magnetic resonance imaging (MRI). The investigators aim to show that the specific metabolite profile and the fat distribution in the Tamil population is associated with the high prevalence of diabetes in this ethnicity. Fat distribution patterns are thought to determine the expression and severity of dysglycaemia. Additionally, the investigators aim to identify the key enzymes, their corresponding genes, and the respective polymorphisms relevant for these metabolic variations.
Who can participate
Age range
18 Years – 75 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Diagnosed with type 2 diabetes per WHO criteria.
* Swiss ethnicity (defined as self-reported ancestry and parents and at least 1 grandparents are from Switzerland)
* Tamil ethnicity (defined as self-reported ancestry and parents and at least 1 grandparents are from Sri Lanka, belonging to ethnic identity of Tamils, respectively)
* Age limit: 18 - 75 years
Exclusion Criteria:
* Subjects with type 1 diabetes, steroid-induced diabetes, gestation diabetes, or pancreoprivic diabetes.
* Subjects with pregnancy.
* Subjects with metal implant, tattoos, or claustrophobia. MRI must be feasible.
* Subjects with severe chronic diseases, e.g. malignancies, heart or renal diseases (\> stage 3).
* Subjects not able to provide informed consent.
* Enrolled in another study.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Metabolic phenotype of type 2 diabetes mellitus across groups